Finance

Lists
Outlook: 24.0% bullish·48.0% bearish
Go to analysis
ABOS:NASDAQ
Acumen Pharmaceuticals Inc
$0.24
+1.63%
(+0.0039) 1D
Nov 3, 9:54:16 AM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABOS...
Open
$0.24
High
$0.25
Low
$0.24
Mkt. cap
17.68M
Avg. vol.
4.06M
Volume
921.19K
52-wk high
$3.60
52-wk low
$0.21
EPS
-$1.55
Beta
0.52
Shares outstanding
72.33M
No. of employees
60
Open
$0.24
High
$0.25
Low
$0.24
Mkt. cap
17.68M
Avg. vol.
4.06M
Volume
921.19K
52-wk high
$3.60
52-wk low
$0.21
EPS
-$1.55
Beta
0.52
Shares outstanding
72.33M
No. of employees
60
News stories
From web sources and news partners
About Acumen Pharmaceuticals Inc
CEO-
Employees60
FoundedJan 1, 1996
HeadquartersNewton, Massachusetts, United States
SectorBiotechnology
Websiteacumenpharm.com
Analyst ratings
Based on 6 analysts giving stock ratings to ABOS in the past 3 months
Hold
Buy
1
Hold
3
Sell
2
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for ABOS in the last 3 months.
Highest
Current $0.24
$1.00 (+310.51%)
Average
$1.00 (+310.51%)
Lowest
$1.00 (+310.51%)
Analyst
Recommendation
Action
Price target
Projected
Date
Dev Prasad
Lucid Capital
Hold
Downgraded
$1.00
+310.5%
11/02/2026
Thomas Shrader
BTIG
Buy
Maintained
$1.00
+310.5%
11/01/2026
Geoff Meacham
Citi
Hold
Downgraded
$1.00
+310.5%
11/02/2026
Pete Stavropoulos
Cantor Fitzgerald
Sell
Downgraded
-
-
10/30/2026
Paul Matteis
Stifel Nicolaus
Hold
Downgraded
$1.00
+310.5%
10/30/2026
Jason Zemansky
Bank of America Securities
Sell
Downgraded
$1.00
+310.5%
10/30/2026
Last report
Oct 26, 2026
Fiscal period
Q3 2026
-$0.35 / -$0.39
+11.29%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
20.53M
16.48M
27.81M
21.11M
Cost of revenue
20.53M
16.48M
27.81M
21.11M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.67M
4.66M
4.75M
4.70M
Operating expense
4.67M
4.66M
4.75M
4.70M
Total operating expenses
25.20M
21.15M
32.56M
25.81M
Operating income
-25.20M
-21.15M
-32.56M
-25.81M
Other non operating income
-174.00K
417.00K
-179.00K
631.00K
EBT including unusual items
-25.14M
-20.74M
-32.72M
-25.37M
EBT excluding unusual items
-25.14M
-20.74M
-32.72M
-25.37M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-25.14M
-20.74M
-32.72M
-25.37M
Net profit margin
-
-
-
-
Earnings per share
-0.41
-0.33
-0.45
-0.35
Interest and investment income
1.32M
1.06M
1.11M
812.00K
Interest expense
-1.09M
-1.07M
-1.09M
-999.00K
Net interest expenses
235.00K
-5.00K
17.00K
-187.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-25.19M
-21.14M
-32.54M
-25.80M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps